ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs MXN
17.75385
0.13%
Brent Oil
83.71
-0.75%
Bitcoin
62,916.70
-2.98%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Arcturus Therapeutics Holdings Inc (ARCT)

  7. Arcturus Therapeutics Holdings Inc (ARCT) Noticias

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ARCT
FechaHoraFuenteTítuloSímboloCompañía
28/02/202215:00Business WireArcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
18/02/202219:00Business WireArcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
17/02/202206:59Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/02/202213:52Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/02/202212:08Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/02/202207:00Business WireArcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/01/202206:46TipRanksArcturus Therapeutics (ARCT) Gets a Hold Rating from H.C. WainwrightNASDAQ:ARCTArcturus Therapeutics Holdings Inc
25/01/202207:00Business WireArcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical TrialNASDAQ:ARCTArcturus Therapeutics Holdings Inc
24/01/202207:00Business WireArcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several VariantsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
18/01/202206:00GlobeNewswire Inc.Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of DirectorsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
06/01/202215:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
16/12/202107:00Business WireArcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical TrialsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
13/12/202107:00Business WireArcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of DirectorsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
22/11/202107:00Business WireArcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/11/202115:00Business WireArcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
25/10/202115:00Business WireArcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021NASDAQ:ARCTArcturus Therapeutics Holdings Inc
21/10/202107:00Business WireArcturus Therapeutics Announces Leadership AppointmentsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/10/202107:00Business WireArcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of ConcernNASDAQ:ARCTArcturus Therapeutics Holdings Inc
22/09/202115:01Business WireArcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine CollaborationNASDAQ:ARCTArcturus Therapeutics Holdings Inc
22/09/202106:00Business WireArcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of ConcernNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/09/202108:00Business WireArcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021NASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/09/202108:00Business WireArcturus Therapeutics to Present at Upcoming Investor and Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/08/202116:09Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/08/202105:05Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/08/202105:01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/08/202115:01Business WireArcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
03/08/202106:00Business WireArcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 StudyNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/08/202108:00Business WireArcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of ConcernNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/08/202106:00Business WireArcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19NASDAQ:ARCTArcturus Therapeutics Holdings Inc
28/07/202107:30Business WireArcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ARCT

Su Consulta Reciente

NYSE
MCD
McDonalds
USOTC
RHHBY
Roche (QX)
NYSE
KO
Coca Cola
NYSE
NKE
Nike
AMEX
XLF
Financial Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
VZ
Verizon Communications
USOTC
ADDYY
Adidas (QX)
USI
USTECH100
US Tech 100
FX
EURMXN
Euro vs MXN
AMEX
SPY
SPDR S&P 500
COIN
ETHUSD
Ethereum
USOTC
BASFY
BASF (QX)
NYSE
AXP
American Express
PM
XAUUSD
Gold vs US Dollar
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados